The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
 
Brian I. Rini
Leadership - MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - 3D Medicines; Aravive; Arrowhead Pharmaceuticals; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Pfizer; Shionogi; Surface Oncology; synthorx
Research Funding - Aravive (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Surface Oncology (Inst); Taris (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Flatiron Health; Genentech/Roche; Infinity Pharmaceuticals; Janssen; MEI Pharma; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Viktor Stus
No Relationships to Disclose
 
Tom Waddell
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Ipsen
 
Rustem Gafanov
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Frédéric Pouliot
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen; Progenics; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Sanofi
Research Funding - Astellas Pharma; Bayer; Sanofi
Expert Testimony - Amgen; Astellas Pharma; Bayer; Sanofi
Travel, Accommodations, Expenses - Bayer; Sanofi
 
Dmitry Nosov
Consulting or Advisory Role - Bayer; Pfizer
 
Bohuslav Melichar
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Lilly; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Lilly; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono
 
Denis Soulieres
Honoraria - Adlai Nortye; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer
Consulting or Advisory Role - Adlai Nortye; Ipsen; Merck; Pfizer
Research Funding - Adlai Nortye (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Delphine Borchiellini
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Pfizer; Roche
 
Ihor O. Vynnychenko
No Relationships to Disclose
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Sergio Jobim Azevedo
No Relationships to Disclose
 
Satoshi Tamada
No Relationships to Disclose
 
Anna Kryzhanivska
No Relationships to Disclose
 
Chenxiang Li
Employment - Merck
 
Joseph E. Burgents
Employment - Merck
Stock and Other Ownership Interests - Merck
 
L. Rhoda Molife
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Jens Bedke
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck KGaA; MSD Oncology; Novartis; Pfizer; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche